FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3047478869> ?p ?o ?g. }

• W3047478869 abstract "Mutations in the LAMA2 gene affect the production of the α2 subunit of laminin-211 (= merosin) and result in either partial or complete laminin-211 deficiency. Complete merosin deficiency is typically associated with a more severe congenital muscular dystrophy, clinically manifested by hypotonia and weakness at birth, the development of contractures of large joints and progressive respiratory involvement. Muscle atrophy and severe weakness typically prevent independent ambulation. Partial merosin deficiency is mostly manifested by later onset limb-girdle weakness and joint contractures so that independent ambulation is typically achieved. Collectively, complete and partial merosin deficiency are referred to as LAMA2-related dystrophies (LAMA2-RDs) and represent one of most common forms of congenital muscular dystrophies worldwide. LAMA2-RDs are classically characterized by both central and peripheral nervous system involvement with abnormal appearing white matter on brain MRI and dystrophic appearing muscle on muscle biopsy as well as creatine kinase levels commonly elevated to > 1,000 IU/L. Next generation sequencing has greatly improved diagnostic abilities for LAMA2-RD, and the majority of patients with merosin deficiency carry recessive pathogenic variants in the LAMA2 gene. The existence of multiple animal models for LAMA2-RDs has helped to advance our understanding of laminin-211 and has been instrumental in preclinical research progress and translation to clinical trials. The first clinical trial for the LAMA2-RDs was a phase 1 pharmacokinetic and safety study of the anti-apoptotic compound omigapil, based on preclinical studies performed in the dyW/dyW and dy2J/dy2Jmouse models. This phase 1 study enabled the collection of pulmonary and motor outcome measures and also provided the opportunity for investigating exploratory outcome measures including muscle ultrasound, muscle MRI and serum and urine biomarker collection. Natural history studies, including a five-year prospective natural history and comparative outcome measures study in patients with LAMA2-RD, have helped to better delineate the natural history and identify viable outcome measures. Plans for further clinical trials for LAMA2-RDs are presently in progress, highlighting the necessity of identifying adequate, disease-relevant biomarkers, capable of reflecting potential therapeutic changes, in addition to refining the clinical outcome measures and time-to-event trajectory analysis of affected patients" @default.
• W3047478869 created "2020-08-10" @default.
• W3047478869 creator A5053346671 @default.
• W3047478869 creator A5058039505 @default.
• W3047478869 creator A5059907230 @default.
• W3047478869 creator A5084391793 @default.
• W3047478869 creator A5089234882 @default.
• W3047478869 date "2020-08-05" @default.
• W3047478869 modified "2023-09-27" @default.
• W3047478869 title "LAMA2-Related Dystrophies: Clinical Phenotypes, Disease Biomarkers, and Clinical Trial Readiness" @default.
• W3047478869 cites W1168009863 @default.
• W3047478869 cites W1422903567 @default.
• W3047478869 cites W1492942312 @default.
• W3047478869 cites W1677773899 @default.
• W3047478869 cites W1866273761 @default.
• W3047478869 cites W1965806327 @default.
• W3047478869 cites W1971466959 @default.
• W3047478869 cites W1973552857 @default.
• W3047478869 cites W1974207676 @default.
• W3047478869 cites W1988920703 @default.
• W3047478869 cites W1990815434 @default.
• W3047478869 cites W1991680249 @default.
• W3047478869 cites W2003665935 @default.
• W3047478869 cites W2007689355 @default.
• W3047478869 cites W2015697497 @default.
• W3047478869 cites W2016768483 @default.
• W3047478869 cites W2019250319 @default.
• W3047478869 cites W2020685420 @default.
• W3047478869 cites W2025615363 @default.
• W3047478869 cites W2027745468 @default.
• W3047478869 cites W2039907188 @default.
• W3047478869 cites W2040206552 @default.
• W3047478869 cites W2045709524 @default.
• W3047478869 cites W2051131650 @default.
• W3047478869 cites W2052748640 @default.
• W3047478869 cites W2054307806 @default.
• W3047478869 cites W2060033256 @default.
• W3047478869 cites W2062234108 @default.
• W3047478869 cites W2065833287 @default.
• W3047478869 cites W2071786947 @default.
• W3047478869 cites W2078980900 @default.
• W3047478869 cites W2079136976 @default.
• W3047478869 cites W2080338828 @default.
• W3047478869 cites W2081525186 @default.
• W3047478869 cites W2084159997 @default.
• W3047478869 cites W2084547669 @default.
• W3047478869 cites W2084703547 @default.
• W3047478869 cites W2087244480 @default.
• W3047478869 cites W2093556738 @default.
• W3047478869 cites W2094299695 @default.
• W3047478869 cites W2100459100 @default.
• W3047478869 cites W2100695719 @default.
• W3047478869 cites W2101732003 @default.
• W3047478869 cites W2106005187 @default.
• W3047478869 cites W2109507582 @default.
• W3047478869 cites W2112139085 @default.
• W3047478869 cites W2113515804 @default.
• W3047478869 cites W2115773976 @default.
• W3047478869 cites W2120088980 @default.
• W3047478869 cites W2120444095 @default.
• W3047478869 cites W2128952479 @default.
• W3047478869 cites W2135604282 @default.
• W3047478869 cites W2137339327 @default.
• W3047478869 cites W2155807506 @default.
• W3047478869 cites W2158739775 @default.
• W3047478869 cites W2167964775 @default.
• W3047478869 cites W2189787157 @default.
• W3047478869 cites W2277280343 @default.
• W3047478869 cites W2546790395 @default.
• W3047478869 cites W2608308548 @default.
• W3047478869 cites W2625678704 @default.
• W3047478869 cites W2724098443 @default.
• W3047478869 cites W2726968290 @default.
• W3047478869 cites W2775276465 @default.
• W3047478869 cites W2784934916 @default.
• W3047478869 cites W2793476428 @default.
• W3047478869 cites W2802855982 @default.
• W3047478869 cites W2803489227 @default.
• W3047478869 cites W2885009200 @default.
• W3047478869 cites W2895038825 @default.
• W3047478869 cites W2918907317 @default.
• W3047478869 cites W2943973726 @default.
• W3047478869 cites W2947870512 @default.
• W3047478869 cites W2963604054 @default.
• W3047478869 cites W2966603223 @default.
• W3047478869 cites W2981622640 @default.
• W3047478869 cites W2982715914 @default.
• W3047478869 cites W3018219574 @default.
• W3047478869 cites W4233918295 @default.
• W3047478869 cites W4285719527 @default.
• W3047478869 doi "https://doi.org/10.3389/fnmol.2020.00123" @default.
• W3047478869 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7419697" @default.
• W3047478869 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32848593" @default.
• W3047478869 hasPublicationYear "2020" @default.
• W3047478869 type Work @default.
• W3047478869 sameAs 3047478869 @default.
• W3047478869 citedByCount "40" @default.
• W3047478869 countsByYear W30474788692021 @default.
• W3047478869 countsByYear W30474788692022 @default.
• W3047478869 countsByYear W30474788692023 @default.

• next